A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and piperaquine (PPQ)

Por Stein, Daniel S, Jain, Jay Prakash, Lickliter, Jason, Kangas, Michael, Machineni, Surendra, Griffin, Paul, Lefevre, Gilbert
Publicado em 2014

Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine

Por Stein, Daniel S., Jain, Jay Prakash, Kangas, Michael, Lefèvre, Gilbert, Machineni, Surendra, Griffin, Paul, Lickliter, Jason
Publicado no Antimicrob Agents Chemother (2015)

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Voluntee...

Por Schluep, Thomas, Lickliter, Jason, Hamilton, James, Lewis, David L., Lai, Ching‐Lung, Lau, Johnson YN, Locarnini, Stephen A., Gish, Robert G., Given, Bruce D.
Publicado no Clin Pharmacol Drug Dev (2016)

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Por Dredge, Keith, Brennan, Todd V., Hammond, Edward, Lickliter, Jason D., Lin, Liwen, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping, Brown, Michael P., Millward, Michael
Publicado no Br J Cancer (2018)

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Por Beran, Jiři, Lickliter, Jason D, Schwarz, Tino F, Johnson, Casey, Chu, Laurence, Domachowske, Joseph B, Van Damme, Pierre, Withanage, Kanchanamala, Fissette, Laurence A, David, Marie-Pierre, Maleux, Koen, Schmidt, Alexander C, Picciolato, Marta, Dieussaert, Ilse
Publicado no J Infect Dis (2018)

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

Por Nebot, Noelia, Arkenau, Hendrik‐Tobias, Infante, Jeffrey R., Chandler, Jason C., Weickhardt, Andrew, Lickliter, Jason D., Sarantopoulos, John, Gordon, Michael S., Mak, Gabriel, St‐Pierre, Annie, Tang, Lihua, Mookerjee, Bijoyesh, Carson, Stanley W., Hayes, Siobhan, Grossmann, Kenneth F.
Publicado no Br J Clin Pharmacol (2018)

ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1

Por Day, Bryan W., Stringer, Brett W., Spanevello, Mark D., Charmsaz, Sara, Jamieson, Paul R., Ensbey, Kathleen S., Carter, Jacinta C., Cox, Joanne M., Ellis, Vicky J., Brown, Christopher L., Walker, David G., Inglis, Po L., Allan, Suzanne, Reynolds, Brent A., Lickliter, Jason D., Boyd, Andrew W.
Publicado em 2011

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volu...

Por Kansagra, Kevinkumar A., Parmar, Deven, Jani, Rajendra H., Srinivas, Nuggehally R., Lickliter, Jason, Patel, Harilal V., Parikh, Devang P., Heading, Heather, Patel, Hardik B., Gupta, Rahul J., Shah, Chintan Y., Patel, Maulik R., Dholakia, Vyom N., Sukhadiya, Raghav, Jain, Mukul R., Parmar, Krupi V., Barot, Kinjal
Publicado no Clin Pharmacokinet (2017)